Logo image
IRO Home Research units Researcher Profiles
Sign in
Drivers of costs associated with reperfusion therapy in acute stroke: the Interventional Management of Stroke III Trial
Journal article   Open access   Peer reviewed

Drivers of costs associated with reperfusion therapy in acute stroke: the Interventional Management of Stroke III Trial

Kit N Simpson, Annie N Simpson, Patrick D Mauldin, Michael D Hill, Sharon D Yeatts, Judith A Spilker, Lydia D Foster, Pooja Khatri, Renee Martin, Edward C Jauch, …
Stroke (1970), Vol.45(6), pp.1791-1798
06/2014
DOI: 10.1161/STROKEAHA.113.003874
PMCID: PMC4128893
PMID: 24876261
url
https://doi.org/10.1161/STROKEAHA.113.003874View
Published (Version of record) Open Access

Abstract

The Interventional Management of Stroke (IMS) III study tested the effect of intravenous tissue-type plasminogen activator (tPA) alone when compared with intravenous tPA followed by endovascular therapy and collected cost data to assess the economic implications of the 2 therapies. This report describes the factors affecting the costs of the initial hospitalization for acute stroke subjects from the United States.
United States Acute Disease Anesthesia, General - economics Costs and Cost Analysis Humans Middle Aged Stroke - economics Tissue Plasminogen Activator - economics Male Thrombolytic Therapy - economics Tissue Plasminogen Activator - therapeutic use Adolescent Adult Female Aged Stroke - therapy

Details

Logo image